M&A / Deals Vertex buys Crinetics for $10bn in endocrinology drive PharmaphorumVertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.Rare DiseaseRead full story pharminent July 7, 2026 (Last updated: July 8, 2026) Pharmaphorum Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: EC approves AbbVie’s Tepkinly combination for follicular lymphomaNext: Vera’s TRUTAKNA Wins FDA Accelerated Approval for IgA Nephropathy Related Stories M&A / Deals Novartis to acquire Myricx Bio in up to $1.5bn deal pharminent July 6, 2026 M&A / Deals Roche looks to Astex in $515m breast cancer deal pharminent July 6, 2026 M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma pharminent July 2, 2026
